Development of Zafirlukast Analogues for Improved Antithrombotic Activity Through Thiol Isomerase Inhibition
Arteriosclerosis, Thrombosis, and Vascular Biology · 2025
DOI: 10.1161/atvbaha.124.321579 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025. Verfasst von Justine A Keovilay und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Administrative Sciences, College of Pharmacy and Health Sciences, Western New England University, Springfield, MA (J…. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Thrombosis, Blood Platelets, Protein Disulfide-Isomerases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Thiol isomerases play essential and nonredundant roles in platelet activation, aggregation, and thrombus formation. Thiol isomerase inhibitors have the potential to overcome the 2 major drawbacks of current antithrombotic therapies, as they target both arterial and venous thrombosis without enhancing bleeding risks. Recently, a Food and Drug Administration–approved drug, zafirlukast (ZAF), was shown to be a promising pan-thiol isomerase inhibitor. The objective of this study is to develop analogues of ZAF with optimized thiol isomerase inhibition and antithrombotic activity. METHODS: Thirty-five ZAF analogues were tested in an insulin turbidometric assay for thiol isomerase inhibition. Analogues were tested for platelet activation, aggregation, P-selectin expression, and laser-induced thrombosis in mice and compared with the parent compound. RESULTS: Of the 35 analogues, 12 retained activity, with 1, compound 21, that demonstrated a greater potency than that of ZAF, 5 had a similar potency to that of ZAF, and 6 had a weaker potency. Analogues demonstrated inhibition of platelet aggregation and P-selectin expression as compared with ZAF, consistent with their potencies. ZAF and compound 21 were shown to be reversible inhibitors of thiol isomerases, and not cytotoxic to cultured, lung, liver, and kidney cells. Finally, in an in vivo assessment of thrombus formation, compound 21 was able to significantly inhibit thrombus formation without affecting bleeding times. CONCLUSIONS: A ZAF analogue, compound 21, with properties superior to those of ZAF was synthesized, demonstrating improved inhibition of platelet activation, aggregation, and thrombus formation as compared with the parent ZAF. This approach could yield a promising clinical candidate for treatment and prophylaxis of arterial and venous thrombosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical and Administrative Sciences, College of Pharmacy and Health Sciences, Western New England University, Springfield, MA (J.A.K., S.E.W., M.K.S., D.R.K.).
- Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, United Kingdom (J.A.K., K.A.T., S.K., T.S., J.M.G., D.R.K.).
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington (K.C.H., N.T.C., C.H., O.V.T., S.G.-T.).
- Department of Medicine, UMass Chan Medical School-Baystate Campus, Springfield (D.R.K.).
ORCID-Profile: Kirk A Taylor, Sabeeya Khan, Tanya Sage, Nishad Thamban Chandrika, Caixia Hou, Jonathan M Gibbins, Sylvie Garneau-Tsodikova, Daniel R Kennedy
Förderung
- NCI NIH HHS
Zitieren
APA
Keovilay, J. A., Howard, K. C., Taylor, K. A., Khan, S., Wurl, S. E., Szahaj, M. K., Sage, T., Chandrika, N. T., Hou, C., Tsodikov, O. V., Gibbins, J. M., Garneau-Tsodikova, S., & Kennedy, D. R. (2025). Development of Zafirlukast Analogues for Improved Antithrombotic Activity Through Thiol Isomerase Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.124.321579
Vancouver
Keovilay JA, Howard KC, Taylor KA, Khan S, Wurl SE, Szahaj MK, et al. Development of Zafirlukast Analogues for Improved Antithrombotic Activity Through Thiol Isomerase Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025. doi:10.1161/atvbaha.124.321579
BibTeX
@article{Keovilay2025,
author = {Keovilay, Justine A and Howard, Kaitlind C and Taylor, Kirk A and Khan, Sabeeya and Wurl, Sienna E and Szahaj, Melanie K and Sage, Tanya and Chandrika, Nishad Thamban and Hou, Caixia and Tsodikov, Oleg V and Gibbins, Jonathan M and Garneau-Tsodikova, Sylvie and Kennedy, Daniel R},
title = {Development of Zafirlukast Analogues for Improved Antithrombotic Activity Through Thiol Isomerase Inhibition},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2025},
doi = {10.1161/atvbaha.124.321579}
}
EUVIMED